This is a working overview of aggregation, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-23 and is reviewed periodically as new material appears.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | typical of a lyophilised peptide preparation |
| Solubility behaviour | pH dependent | lowest near the isoelectric point |
| Storage of bulk material | Minus 20 degrees Celsius or below | protect from light and moisture |
| Storage of unused pen | 2 to 8 degrees Celsius | do not freeze |
| Common assay method | Reversed-phase HPLC | identity, purity and content |
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
The melanocyte-stimulating hormones, known collectively as MSH, also known as melanotropins or intermedins, are a family of peptide hormones and neuropeptides consisting of α-melanocyte-stimulating hormone (α-MSH), β-melanocyte-stimulating hormone (β-MSH), and γ-melanocyte-stimulating hormone (γ-MSH) that are produced by cells in the pars intermedia of the anterior lobe of the pituitary gland. Synthetic analogues of α-MSH, such as afamelanotide (melanotan I; Scenesse), melanotan II, and bremelanotide (PT-141), have been developed and researched.
When medications do not include specific disposal instructions, patients should not flush medications in the toilet, but instead use medication take-back programs to reduce the amount of pharmaceutical waste in sewage and landfills. If no take-back programs are available, prescription drugs can be discarded in household trash after they are crushed or dissolved and then mixed in a separate container or sealable bag with undesirable substances like cat litter or other unappealing material (to discourage consumption).
== Properties of RNA == The properties of RNA make the idea of the RNA world hypothesis conceptually plausible, though its general acceptance as an explanation for the origin of life requires further evidence. RNA is known to form efficient catalysts, and its similarity to DNA makes clear its ability to store information. Opinions differ, however, as to whether RNA constituted the first autonomous self-replicating system or was a derivative of a still-earlier system. One version of the hypothesis is that a different type of nucleic acid, termed pre-RNA, was the first one to emerge as a self-reproducing molecule, to be replaced by RNA only later. On the other hand, the discovery in 2009 that activated pyrimidine ribonucleotides can be synthesized under plausible prebiotic conditions suggests that it is premature to dismiss the RNA-first scenarios. Suggestions for 'simple' pre-RNA nucleic acids have included peptide nucleic acid (PNA), threose nucleic acid (TNA) or glycol nucleic acid (GNA). Despite their structural simplicity and possession of properties comparable with RNA, the chemically plausible generation of "simpler" nucleic acids under prebiotic conditions has yet to be demonstrated.
Sources: en.wikipedia.org
==== Depreciation tax deduction ==== For qualified production property of a taxpayer, the law makes permanent a 100% Section 179 depreciation deduction for the adjusted basis for the property acquired after January 19, 2025. Businesses are allowed to take a section 179 tax deduction for the cost of certain business property, software, leasehold improvements, and water utility property rather than deduct only the amount depreciated each year. Under the law, the maximum tax deduction is permanently increased from $1 million to $2.5 million and then phased out to $4 million, all of which will be indexed for inflation in future years. These changes are effective for tax years beginning after December 31, 2024. The law also created a new depreciation allowance for nonresidential real property that is used as an essential part of an activity that includes the manufacturing, production, or refining of certain tangible products that significantly transforms the product. Types of property that do not qualify include nonresidential real property used for offices, administrative services, lodging, parking, sales activities, software development, and software engineering. The property's construction must begin between January 20, 2025, and December 31, 2028, and it must be placed in service in the U.S. or U.S. possessions on or before December 31, 2030.
A December 2023 study by the Network Contagion Research Institute (NCRI) found a "strong possibility that content on TikTok is either amplified or suppressed based on its alignment with the interests of the Chinese government." According to its director, the NCRI is an independent non-profit research organization funded by Rutgers University, the British government, and private donors. The New York Times commented that "[a]lready, there is evidence that China uses TikTok as a propaganda tool. Posts related to subjects that the Chinese government wants to suppress — like Hong Kong protests and Tibet — are strangely missing from the platform." TikTok subsequently restricted the number of hashtags that can be searched under its Creative Center, saying it was "misused to draw inaccurate conclusions". A historian from the Cato Institute said that there were "basic errors" in the Rutgers University study and criticized the uncritical news coverage that followed. The study compares data from before TikTok even existed to show the app has fewer hashtags about historically sensitive topics, distorting the findings. In August 2024, the NCRI released a subsequent report based on user journey data from 24 accounts that they created across TikTok, Instagram, and YouTube. By searching for four keywords—Uyghur, Xinjiang, Tibet, and Tiananmen, the researchers found that TikTok returned a higher percentage of positive, neutral, or irrelevant content related to human rights in China.
=== Category:EC 1.20 (act on phosphorus or arsenic as donors) === Category:EC 1.20.1 Category:EC 1.20.2 Category:EC 1.20.4 Arsenate reductase (glutaredoxin) EC 1.20.4.1 Glutaredoxin Category:EC 1.20.9 Category:EC 1.20.99
Sources: en.wikipedia.org
Griffin, J. P. (2004). "Venetian treacle and the foundation of medicines regulation". British Journal of Clinical Pharmacology. 58 (3): 317–325. doi:10.1111/j.1365-2125.2004.02147.x. PMC 1884566. PMID 15327592. Raj D, Pękacka-Falkowska K, Włodarczyk M, Węglorz J. The real Theriac - panacea, poisonous drug or quackery? J Ethnopharmacol. 2021 Dec 5;281:114535. doi: 10.1016/j.jep.2021.114535. Epub 2021 Aug 17. PMID: 34416297.
=== Bovine β-casomorphin 7 === Structure: YPFPGPI Chemical formula: C41H55N7O9 Molecular weight: 789.9 g/mol bBCM7 is produced in when digesting bovine A1 beta-casein outside of the body using pancreatic enzymes, and inside of some animal bodies. The A2 form, which follows Ile with a Pro instead of a His, is more resistant to the release of bBCM7, presumably because the proline residue blocks the action of a carboxyl peptidase. bBCM7 has significant opioid effects when injected (and in more recent research, orally fed) into animals, but human studies supporting the use of "bBCM7-free" A2 milk is still lacking.
Airways, including hilar adenopathy or enlargement Breast shadows Bones, e.g. rib fractures and lytic bone lesions Cardiac silhouette, detecting cardiac enlargement Costophrenic angles, including pleural effusions Diaphragm, e.g. evidence of free air, indicative of perforation of an abdominal viscus Edges, e.g. apices for fibrosis, pneumothorax, pleural thickening or plaques Extrathoracic tissues Fields (lung parenchyma), being evidence of alveolar flooding Failure, e.g. alveolar air space disease with prominent vascularity with or without pleural effusions
=== Conditionality === The general principle of conditionality is expressed in numerous early sources as "When this is, that is; This arising, that arises; When this is not, that is not; This ceasing, that ceases." According to Rupert Gethin, this basic principle is neither a direct Newtonian-like causality nor a singular form of causality. Rather, it asserts an indirect and plural conditionality which is somewhat different from classic European views on causation. The Buddhist concept of dependence is referring to conditions created by a plurality of causes that necessarily co-originate phenomena within and across lifetimes, such as karma in one life creating conditions that lead to rebirth in a certain realm of existence for another lifetime. Bhikkhu Bodhi writes that the Buddhist principle of conditionality "shows that the "texture" of being is through and through relational." Furthermore, he notes that dependent arising goes further than just presenting a general theory about conditionality, it also teaches a specific conditionality (idappaccayatā), which explains change in terms of specific conditions. Dependent arising therefore also explains the structure of relationships between specific types of phenomena (in various interlocking sequences) which lead to suffering as well as the ending of suffering.
Sources: en.wikipedia.org
Ice formation concentrates solutes and can mechanically stress the peptide or damage the delivery device. Thawing afterwards may leave aggregates that are not visible to the eye. Refrigeration keeps the solution above its freezing point while slowing chemical degradation.
Size-exclusion chromatography is the most common technique, separating monomer from dimer and higher-order species by hydrodynamic volume. It is usually paired with ultraviolet detection and, for trace work, with multi-angle light scattering. Results depend on mobile-phase conditions, so method details matter when comparing datasets.
The detailed degradation profile under real-world temperature excursions and repeated handling is not fully described in the open literature. Relative contributions of photo-degradation versus thermal pathways are also incompletely mapped. Whether specific impurity species carry different biological activity is an open question rather than an established finding.
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.